The Recall Desk
LowFDA (Drugs)·D-1392-2019·Announced 2019-06-26

Akorn Recalls Myorisan Isotretinoin Capsules Due to Labeling Error

Akorn Inc. is recalling 16,216 cartons of Myorisan isotretinoin capsules because secondary cartons incorrectly state 40 mg instead of 30 mg.

What this means for you

Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.

Our severity reasoning: The recall is classified as FDA Class III, which by definition is unlikely to cause adverse health consequences, and the issue is a minor labeling error on the secondary packaging.

Plain-English summary

Akorn Inc. is recalling 16,216 cartons of Myorisan (isotretinoin capsules, USP), 40 mg, NDC 61748-304-13. The recall is due to a labeling error where the secondary carton erroneously states 40 mg instead of 30 mg, although the primary carton is labeled correctly.

The affected product is distributed nationwide in the United States. The specific lot number is V30M56A with an expiration date of 9/20.

Consumers should check their medication packaging for the incorrect secondary carton label. If the product matches the description, they should contact their pharmacist or healthcare provider for guidance on the appropriate action.

The recalled product

Product
Myorisan (isotretinoin capsules, USP), 40 mg, packaged in cartons of 30 Capsules containing 3 x 10 Prescription Packs, Rx Only, Distributed by: VersaPharm Inc. - An Akorn Company, Lake Forest, IL 60045, NDC 61748-304-13
Manufacturer
Akorn Inc
Affected units
16,216

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot#: V30M56A
  • Exp 9/20

Distribution

Distributed nationwide across the United States.